Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efinopegdutide vs Semaglutide in NAFLD
NCT04944992Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2021
- Primary completion
- Oct 2022
- Modality
- Peptides
- Countries
- 16
01
Overview
A Phase 2 trial of efinopegdutide in non-alcoholic fatty liver disease (NAFLD), Nonalcoholic steatohepatitis (NASH), sponsored by Merck & Co.. Started Aug 2021; status: completed.
02
Drugs
efinopegdutide
03
Conditions
non-alcoholic fatty liver disease (NAFLD)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04944992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04944992.